Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock [Seeking Alpha]
Fulgent Genetics, Inc. (FLGT)
Last fulgent genetics, inc. earnings: 3/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fulgentgenetics.com
Company Research
Source: Seeking Alpha
FLGT's diagnostics business is growing, with 15.4% revenue growth YTD and all segments contributing, notably BioPharma services up 72%. Management is highly aligned, owning 33% of shares, executing opportunistic buybacks, and prioritizing disciplined M&A for further growth. I maintain a Buy rating, though upside is less compelling after a 50% rally; the opportunity now hinges on management execution and long-term optionality. Solskin/DigitalVision via Getty Images It's been over a year since I covered Fulgent Genetics ( FLGT ), a biotech company focusing on cancer cures. On my first look, I saw a company trading significantly below the net value of This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of FLGT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business rel
Show less
Read more
Impact Snapshot
Event Time:
FLGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FLGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FLGT alerts
High impacting Fulgent Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
FLGT
News
- Fulgent Genetics (NASDAQ:FLGT) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- Fulgent Genetics to Acquire Bako Diagnostics Assets and StrataDx for $55.5 Million [Los Angeles Times (CA)]Los Angeles Times
- Fulgent Genetics to buy Bako Diagnostics assets and StrataDx [Yahoo! Finance]Yahoo! Finance
- Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx [Yahoo! Finance]Yahoo! Finance
- Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDxBusiness Wire
FLGT
Earnings
- 11/7/25 - Beat
FLGT
Analyst Actions
- 11/14/25 - Raymond James Financial, Inc.
FLGT
Sec Filings
- 1/28/26 - Form 4
- 1/28/26 - Form 4
- 1/28/26 - Form 4
- FLGT's page on the SEC website